Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir

British Journal of Clinical Pharmacology

Volumn 69, Issue 1, 2010, Pages 51-57

  Andrews, Emma ^a   Glue, Paul ^a   Fang, Juanzhi ^b   Crownover, Penelope ^a   Tressler, Randall ^a   Damle, Bharat ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Maraviroc; Pharmacokinetics; Raltegravir

Indexed keywords

MARAVIROC; RALTEGRAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD SAMPLING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DRUG SAFETY; DYSPEPSIA; FEMALE; FOLLICULITIS; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM ALLOWABLE CONCENTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SOMNOLENCE;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 72949119327     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03546.x     Document Type: Article

References (19)

1. World Heath Organization. 2007 AIDS Epidemic Update. Available at http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf (last accessed 2 October 2009).
2. Wilson LE, Gallant JE. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations. Clin Infect Dis 2009 48 : 214 221.
3. Chen TK, Aldrovandi GM. Review of HIV antiretroviral drug resistance. Pediatr Infect Dis J 2008 27 : 749 752.
4. Marviroc (Selzentry®). United States Prescribing Information. New York : Pfizer Inc., 2008.
5. MacArthur RD, Novak RM. Reviews of anti-infective agents: Maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008 47 : 236 241.
6. Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 2008 65 (Suppl. 1 60 7.
7. Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008 65 (Suppl. 1 27 37.
8. Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008 65 (Suppl. 1 38 46.
9. Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, Muirhead GJ. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008 65 (Suppl. 1 5 18.
10. Raltegravir (Isentress®). United States Prescribing Information. Whitehouse Station, NJ : Merck & Co. Inc., 2007.
11. Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin Ther 2008 30 : 1747 1765.
12. Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Merschman SA, Strohmaier KM, Ramael S, Lasseter KC, Stone JA, Gottesdiener KM, Wagner JA. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008 83 : 293 299.
13. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, Wenning LA. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007 35 : 1657 1663.
14. Merck. ISENTRESS™ (raltegravir) 400 mg For Treatment of HIV (NDA 22-145 2007. Briefing Document. Presented as part of the FDA Antiviral Drugs Advisory Committee meeting, held September 5, 2007. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4314b1-01-Merck.pdf (last accessed 6 March 2009).
15. Nozza S, Visco F, Soria A, Galli L, Salpietro S, Gianotti N, Carini E, Bigoloni A, Fusetti G, Tambussi G, Lazzarin A, Castagna A. Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine. 9th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 9-13 November 2008. Abstract P045.
16. Merschman SA, Vallano PT, Wenning LA, Matuszewski BK, Woolf EJ. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J Chromatogr 2007 857 : 15 24.
17. McFadyen L, Jacqmin P, Wade JR, Weatherley B, Chan PLS. Maraviroc (MVC) exposure-efficacy relationship HIV-1-infected patients. 11th European AIDS Conference / EACS. Madrid, Spain, 24-27 October 2007. Poster P4.1/06.
18. McFadyen L, Jacqmin P, Wade JR, Weatherley B. Maraviroc exposure-efficacy (<50 copies/mL) analysis in HIV-1-infected treatment-naïve subjects - ITT Population (MERIT Study). XVII International AIDS Conference, Mexico City, Mexico, 3-8 August 2008. Poster TUPE0053.
19. Wenning L, Nguyen BY, Sun X, Hwang E, Chen Y, Teppler H, Harvey C, Rhodes R, Ryan D, Azrolan N, Stone J. Pharmacokinetic/pharmacodynamic (PK/PD) analyses of raltegravir in phase II and III studies in treatment-experienced HIV patients. 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, USA, 7-9 April 2008.